Related Experiment Video
Updated: Aug 16, 2026
11:34
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis
Meiling Yu1,2,3, Huizhu Tan1,2, Kuirong Mao1,2
1Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital of Jilin University, Changchun, Jilin, 130062, China.
Materials Today. Bio
|August 15, 2026
Summary
Nanoparticles silenced CD40 in immune cells, reprogramming them to reduce inflammation and fibrosis in experimental autoimmune myocarditis. This approach offers a new strategy for treating inflammatory heart disease.
Area of Science:
- Immunology
- Cardiovascular Medicine
- Biomaterials Science
Background:
- Autoimmune myocarditis can lead to heart failure, with limited treatment options.
- Dendritic cells (DCs) play a key role in driving cardiac inflammation by disrupting immune tolerance.
- Targeting antigen-presenting cells offers a potential therapeutic avenue.
Purpose of the Study:
- To investigate a nanoparticle-based strategy for CD40 silencing in myeloid antigen-presenting cells.
- To assess the potential of this strategy for immune tolerance programming in experimental autoimmune myocarditis.
- To evaluate the therapeutic efficacy and underlying mechanisms of CD40 silencing.
Main Methods:
- Development of a polymer-lipid hybrid nanoparticle formulation carrying siRNA targeting CD40 (siCD40/NP).
- Administration of siCD40/NP to induce sustained CD40 silencing in myeloid antigen-presenting cells.
- Analysis of DC reprogramming, immune cell populations (Tregs, Breg), cytokine profiles, cardiac inflammation, fibrosis, and ventricular function.
Main Results:
- Sustained CD40 silencing in myeloid antigen-presenting cells and reprogramming of DCs to a tolerogenic phenotype.
- Induction of regulatory T cells and IL-10-producing regulatory B cells, with suppression of Th17 responses.
- Significant attenuation of myocardial inflammation and fibrosis, preservation of ventricular function, and no systemic toxicity.
Conclusions:
- Nanoparticle-enabled CD40 silencing is a viable materials-based strategy for immune tolerance programming.
- Reprogramming antigen-presenting cells is a promising approach for developing immunoregulatory biomaterials for inflammatory heart disease.
- The findings highlight a potential new therapeutic modality for autoimmune myocarditis and related conditions.
